Palvella Therapeutics’ COO Executes Planned 10b‑5 Trade: No Shock to the Market, Just Routine Portfolio Management
Investor insight: Palvella Therapeutics insider trades show routine portfolio management, not a price shift, amid a 52‑week low and negative earnings.
4 minutes to read